Patents by Inventor Michael CERTO

Michael CERTO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20250262323
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PCSK9 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of hypercholesterolemia or a condition associated therewith.
    Type: Application
    Filed: April 21, 2025
    Publication date: August 21, 2025
    Applicant: Novo Nordisk A/S
    Inventors: Jordan JARJOUR, Kyle HAVENS, Michael CERTO, Max ECHTERLING
  • PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20240189454
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PCSK9 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of hypercholesterolemia or a condition associated therewith.
    Type: Application
    Filed: August 30, 2023
    Publication date: June 13, 2024
    Applicant: 2Seventy bio, Inc.
    Inventors: Jordan JARJOUR, Kyle HAVENS, Michael CERTO, Max ECHTERLING
  • PCSK9 endonuclease variants, compositions, and methods of use
    Patent number: 11779654
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PCSK9 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of hypercholesterolemia or a condition associated therewith.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: October 10, 2023
    Assignee: 2SEVENTY BIO, INC.
    Inventors: Jordan Jarjour, Kyle Havens, Michael Certo, Max Echterling
  • MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF
    Publication number: 20230287111
    Abstract: The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.
    Type: Application
    Filed: November 10, 2022
    Publication date: September 14, 2023
    Inventors: Jordan Jarjour, Alexander Astrakhan, Michael Certo
  • Multipartite signaling proteins and uses thereof
    Patent number: 11530265
    Abstract: The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease. As a preferred example, the present disclosure relates to fusion polypeptides comprising (a) a first polypeptide comprising a first secretion signal, a first multimerization domain, a first transmembrane domain, and an actuator domain, (b) a viral self-cleaving polypeptide, and (c) a second polypeptide comprising a second secretion signal, a binding domain that comprises a single chain antibody, a receptor ectodomain, or a ligand, a second multimerization domain, and a second transmembrane domain.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: December 20, 2022
    Assignee: 2seventy bio, Inc.
    Inventors: Jordan Jarjour, Alexander Astrakhan, Michael Certo
  • PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
    Publication number: 20200376140
    Abstract: The present disclosure provides improved genome editing compositions and methods for editing a PCSK9 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of hypercholesterolemia or a condition associated therewith.
    Type: Application
    Filed: October 4, 2018
    Publication date: December 3, 2020
    Applicant: bluebird bio, Inc.
    Inventors: JORDAN JARJOUR, KYLE HAVENS, MICHAEL CERTO, MAX ECHTERLING
  • MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF
    Publication number: 20200071401
    Abstract: The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.
    Type: Application
    Filed: September 17, 2019
    Publication date: March 5, 2020
    Applicant: bluebird bio, Inc.
    Inventors: Jordan JARJOUR, Alexander ASTRAKHAN, Michael CERTO
  • MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF
    Publication number: 20200071399
    Abstract: The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.
    Type: Application
    Filed: August 14, 2019
    Publication date: March 5, 2020
    Applicant: bluebird bio, Inc.
    Inventors: Jordan Jarjour, Alexander Astrakhan, Michael Certo
  • Multipartite signaling proteins and uses thereof
    Patent number: 10457731
    Abstract: Nucleic acids that encode chemically-inducible fusion proteins, vectors that contain nucleic acids that encode chemically-inducible fusion proteins, chemically-inducible fusion proteins, chemically-inducible fusion protein complexes, and non-natural cells that are modified to express chemically-inducible fusion proteins to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: October 29, 2019
    Assignee: bluebird bio, Inc.
    Inventors: Jordan Jarjour, Alexander Astrakhan, Michael Certo
  • Multipartite signaling proteins and uses thereof
    Patent number: 10428142
    Abstract: The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: October 1, 2019
    Assignee: bluebird bio, Inc.
    Inventors: Jordan Jarjour, Alexander Astrakhan, Michael Certo
  • MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF
    Publication number: 20190112372
    Abstract: The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 18, 2019
    Applicant: bluebird bio, Inc.
    Inventors: Jordan JARJOUR, Alexander ASTRAKHAN, Michael CERTO
  • Multipartite signaling proteins and uses thereof
    Patent number: 10196444
    Abstract: The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: February 5, 2019
    Assignee: bluebird bio, Inc.
    Inventors: Jordan Jarjour, Alexander Astrakhan, Michael Certo
  • MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF
    Publication number: 20160311901
    Abstract: The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.
    Type: Application
    Filed: July 23, 2014
    Publication date: October 27, 2016
    Inventors: Jordan JARJOUR, Alexander ASTRAKHAN, Michael CERTO
  • MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF
    Publication number: 20150266973
    Abstract: The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.
    Type: Application
    Filed: January 28, 2015
    Publication date: September 24, 2015
    Inventors: Jordan JARJOUR, Alexander ASTRAKHAN, Michael CERTO